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Multiple sclerosis is a chronic inflammatory, demyelinating disease, although it has been suggested that in the progressive late phase, in-
flammatory lesion activity declines. We recently showed in the Netherlands Brain Bank multiple sclerosis-autopsy cohort considerable
ongoing inflammatory lesion activity also at the end stage of the disease, based on microglia/macrophage activity. We have now studied
the role of T cells in this ongoing inflammatory lesion activity in chronic multiple sclerosis autopsy cases. We quantified T cells and
perivascular T-cell cuffing at a standardized location in the medulla oblongata in 146 multiple sclerosis, 20 neurodegenerative control
and 20 non-neurological control brain donors. In addition, we quantified CD3+, CD4+, and CD8+ T cells in 140 subcortical white
matter lesions. The location of CD8+ T cells in either the perivascular space or the brain parenchyma was determined using CD8/lam-
inin staining and confocal imaging. Finally, we analysed CD8+ T cells, isolated from fresh autopsy tissues from subcortical multiple
sclerosis white matter lesions (n = 8), multiple sclerosis normal-appearing white matter (n = 7), and control white matter (n = 10), by
flow cytometry. In normal-appearing white matter, the number of T cells was increased compared to control white matter. In active
and mixed active/inactive lesions, the number of T cells was further augmented compared to normal-appearing white matter. Active
and mixed active/inactive lesions were enriched for both CD4+ and CD8+ T cells, the latter being more abundant in all lesion types.
Perivascular clustering of T cells in the medulla oblongata was only found in cases with a progressive disease course and correlated
with a higher percentage of mixed active/inactive lesions and a higher lesion load compared to cases without perivascular clusters in
the medulla oblongata. In all white matter samples, CD8+ T cells were located mostly in the perivascular space, whereas in mixed ac-
tive/inactive lesions, 16.3% of the CD8+ T cells were encountered in the brain parenchyma. CD8+ T cells from mixed active/inactive
lesions showed a tissue-resident memory phenotype with expression of CD69, CD103, CD44, CD49a, and PD-1 and absence of S1P1.
They upregulated markers for homing (CXCR6), reactivation (Ki-67), and cytotoxicity (GPR56), yet lacked the cytolytic enzyme gran-
zyme B. These data show that in chronic progressive multiple sclerosis cases, inflammatory lesion activity and demyelinated lesion load
is associated with an increased number of T cells clustering in the perivascular space. Inflammatory active multiple sclerosis lesions are
populated by CD8+ tissue-resident memory T cells, which show signs of reactivation and infiltration of the brain parenchyma.
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Introduction
Relapsing-remitting multiple sclerosis is at its onset charac-
terized by a relatively high frequency of clinical exacerba-
tions and gadolinium-enhancing lesions on brain MRI
(McFarland et al., 1996; Vollmer, 2007; Thompson et al.,
2018). These phenomena are believed to reflect waves of in-
flammatory cells trafficking from the circulation through the
blood–brain barrier into the CNS causing focal demyelinat-
ing lesions. Invading T cells have been proposed to play a
central role in the early disease process of multiple sclerosis
(Dendrou et al., 2015). At later stages, both relapse rate and
lesion enhancement often decline to near zero (McFarland
et al., 1996; Vollmer, 2007; Thompson et al., 2018).
Patients with advanced multiple sclerosis often experience a
continuous deterioration of neurological functions referred
to as progressive multiple sclerosis (Thompson et al., 2018).
Clinical trials of drugs targeting circulating leucocytes are
mostly negative on their primary end points in progressive
multiple sclerosis. Advanced multiple sclerosis is therefore
sometimes referred to as a disease driven by neurodegenera-
tive mechanisms rather than inflammatory mechanisms
(Mahad et al., 2015).
When performing an immunohistochemical analysis of a
large collection of post-mortem multiple sclerosis brains, we
encountered mixed active/inactive (previously referred to as
chronic active) lesions containing HLA+ macrophages in
78% of brain donors with advanced multiple sclerosis
(Luchetti et al., 2018). In this autopsy cohort, the percentage
of mixed active/inactive lesions correlated with a faster ac-
crual of multiple sclerosis-related disability (Luchetti et al.,
2018). Earlier studies suggest a role of T cells in this ongoing
inflammatory response in patients with chronic multiple
sclerosis, as perivascular inflammatory infiltrates are found
in association with mixed active/inactive lesions, specifically
in secondary progressive multiple sclerosis cases (Revesz
et al., 1994). These T cells mostly express CD8 (Booss et al.,
1983; Hayashi et al., 1988; Frischer et al., 2009; van Nierop
et al., 2017; Machado-Santos et al., 2018) and display signs
of clonal expansion (Babbe et al., 2000). Whether T cells
also critically contribute to the ongoing inflammation in
advanced multiple sclerosis, where signs of trafficking im-
mune cells through the blood–brain barrier are generally
lacking, is uncertain.
Recently, we characterized T cells in normal human
brain white matter by flow-cytometric analysis of rapid
post-mortem autopsy tissue (Smolders et al., 2013, 2018).
We observed low numbers of predominantly CD8+ T cells,
almost exclusively residing in the perivascular space (PVS),
with a phenotype resembling the core profile of tissue-resi-
dent memory T (TRM) cells (Smolders et al., 2018). In
several tissues, viral antigen-specific CD8+ TRM cell popu-
lations that arise after a first viral infection are character-
ized by a set of surface markers including the C-type lectin
CD69 and the alpha E integrin CD103. These cells do not
recirculate but are retained locally to become reactivated in
the case of renewed viral exposure (Szabo et al., 2019).
CNS TRM cell populations also develop after experimental
neurotropic virus infection (Aguilar-Valenzuela et al.,
2018; Schøller et al., 2019; Shwetank et al., 2019).
Evidence suggests that multiple sclerosis-associated T-cell
populations express markers associated with TRM cells.
Sørensen et al. (1999) found both CXC chemokine recep-
tor (CXCR)3 and C-C chemokine receptor (CCR)5 expres-
sion by perivascular cuff and lesional T cells. Machado-
Santos et al. (2018) described a loss of the recirculation
markers sphingosine-1-phosphate receptor 1 (S1P1) and
CCR7, and an upregulation of CD103 and CCR5, but not
CD69, by lesional CD8+ T cells. Contrastingly, van
Nierop et al. (2017) found no expression of CD103 but ra-
ther expression of CD69 by CD8+ T cells. Whether white
matter lesion-associated T cells are bona fide TRM cells and
contribute as such to chronic multiple sclerosis lesion activ-
ity remained to be consolidated.
We here used a combination of immunohistochemistry
and flow cytometry to study the localization, quantity, and
phenotype of CD8+ T cells in association with multiple
sclerosis normal-appearing white matter and white matter
lesions.
Material and methods
Donors and tissue characteristics
One hundred and forty-six multiple sclerosis brain donors
from the Netherlands Brain Bank were included in the ana-
lysis of T cells in multiple sclerosis lesions. Informed consent
was given by the donors for brain autopsy and for the use
of material and clinical data for research purposes, in com-
pliance with national ethical guidelines. The Netherlands
Brain Bank autopsy procedures were approved by the
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Medical Ethics Committee of the VU Medical Center,
Amsterdam, The Netherlands. The donors came to autopsy
between 1991 and 2015. The clinical diagnosis of multiple
sclerosis was confirmed for all patients, and the clinical
course was defined as relapsing (for both relapsing-remitting
and progressive relapsing cases), secondary progressive, or
primary progressive by a certified neurologist according to
McDonald or Poser criteria. The diagnosis of multiple scler-
osis was confirmed by a certified neuropathologist.
T cells and perivascular cuffing were examined in the
standardly dissected brainstem at the level of the medulla
oblongata. The brainstem allowed a standardized compari-
son between multiple sclerosis autopsy cases in a functional-
ly important white matter tract. Brainstem tissue blocks
were obtained from 146 multiple sclerosis cases, 20
Alzheimer’s disease cases (Braak score 45), and 20 non-
neurological controls (Table 1). To correlate T-cell numbers
with stages of multiple sclerosis lesion pathology, subcortical
white matter lesions were studied. Subcortical white matter
tissue blocks from 57 multiple sclerosis donors containing
140 multiple sclerosis white matter lesions were obtained to-
gether with subcortical white matter from 20 Alzheimer’s
disease cases (Braak score 45) and 18 non-neurological
controls. Treatment status for immunomodulatory therapies
(fingolimod, natalizumab, or interferon beta) in the year be-
fore death was obtained from the clinical files. From the
total 146 multiple sclerosis cases, one had received
fingolimod.
Biopsy tissue sections containing inflammatory active mul-
tiple sclerosis lesions from six donors were made available
by the Institute for Neuropathology, University Hospital
Mu¨nster, Germany upon approval by the local Medical
Ethics Committee. For donor information, see
Supplementary Table 1.
Characterization of multiple
sclerosis lesion activity and
perivascular T cell cuffing
All brainstem and subcortical white matter tissue sections
were immunostained for proteolipid protein (PLP) and
human leucocyte antigen (HLA-DR/DQ, referred to as
HLA) as previously described (Luchetti et al., 2018; Fransen
et al., 2019). Reactive, active, mixed active/inactive, inactive
and inactive remyelinated lesions were distinguished. Lesions
were annotated, and adjacent sections were stained for CD3
and counterstained with cresyl violet. All tissue sections
were systematically examined with the microscope at 20
magnification, while the observer was blind for the clinical
disease course. Perivascular T cell cuffing was considered
present when more than one ring of CD3+ T cells was pre-
sent in the PVS (Revesz et al., 1994).
Immunohistochemistry and
quantification of T cell numbers
Adjacent 8-mm formalin-fixed, paraffin-embedded sections
were immunostained for CD3, CD4, and CD8 without nu-
clear counterstaining. Antigen retrieval was accomplished
with microwave treatment at 700 W. Endogenous peroxid-
ase activity and non-specific binding were blocked as
described previously (Fransen et al., 2019). Sections were
incubated with a primary antibody overnight in blocking
buffer at 4C (details on primary antibodies and concentra-
tions are provided in Supplementary Table 2). The appropri-
ate biotinylated, secondary antibody was applied, followed
by conjugation with avidin-biotin horseradish peroxidase
(HRP) complex (Vector Elite ABC kit; Vector Laboratories).
Alternatively, an anti-rabbit secondary antibody directly
conjugated with HRP (REALTM EnVisionTM Detection
System; Dako) was applied to the CD8-stained sections.
Visualization was established with 3,30-diaminobenzidine
chromogen.
Brightfield tiled images of tissue sections were taken using
an Axioscope microscope (Zeiss) while using a green filter to
obtain monochromatic light with a 10 Zeiss Plan-
Neofluar objective and a black and white camera (XC-77;
Sony). To outline the lesions and the normal-appearing
white matter, an overlay was made in Adobe Photoshop CC
(version 19.1.2; Adobe Systems, San Jose, CA, USA) of the
CD3-, CD4-, and CD8-stained sections with the correspond-
ing images of the HLA-PLP-stained section. Areas of interest
were manually outlined with Image-Pro Plus 6.3 software
(Media Cybernetics, Rockville, MD, USA). For each stain-
ing, the background optical density (OD) was measured for
all sections. Subsequently, the OD threshold for a positive
cell signal was set at four times the average background. OD
Table 1 Donor and sample information for immunohistochemistry
Diagnosis Cases, n Age, years Sex,
female/male
PMD,
h:min
pH value Brain
weight, g
Disease duration,
years
Multiple sclerosis 146 64.6 ± 13.1 94/52 8:58 ± 6:12 6.5 ± 0.3 1.202 ± 146 30.0 ± 13.4
Relapsing-remitting 15 64.2 ± 16.3 10/5 11:12 ± 13:18 6.5 ± 0.4 1.214 ± 100 24.9 ± 11.8
Primary progressive 49 67.9 ± 13.0 31/18 8:06 ± 2:27 6.5 ± 0.3 1.194 ± 132 28.6 ± 12.3
Secondary progressive 82 62.8 ± 12.2 53/29 9:04 ± 5:45 6.5 ± 0.3 1.186 ± 141 31.8 ± 14.2
Neurodegenerative controls
(Alzheimer’s disease)
20 65.2 ± 6,35 11/9 5:37 ± 1:41 6.5 ± 0.2 1.125 ± 183 –
Non-neurological controls 20 63.6 ± 11.0 14/6 9:08 ± 4:19 6.5 ± 0.4 1.270 ± 175 –
Values are provided as mean ± SD (standard deviation). PMD = post-mortem delay.
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particles with size between 10 and 100 mm2 (Downey et al.,
1990), exceeding the OD threshold, were counted as CD3+,
CD4+ , or CD8+ T cells using Image Pro-Plus (Zhu et al.,
2016). An example of the mask, created for the particle ana-
lysis of CD3 and CD4 immunostainings, is shown in
Supplementary Fig. 1. All masks were visually inspected for
disturbances.
Axonal quantification by
Bielschowsky silver staining
Axonal density in pyramidal tract normal-appearing white
matter was examined in 76 multiple sclerosis and 13 control
cases. Bielschowsky silver staining was performed by placing
8-mm thick paraffin-embedded, formalin-fixed tissue sections
in Milli-QV
R
water, followed by preheated 20% silver nitrate
solution, in a dark oven at 40C. Then, 32% ammonium
hydroxide was added until the solution turned colourless,
and sections were incubated at 40C. Next, the sections
were placed in 1% ammonium hydroxide solution, and de-
veloper solution was added to this solution. The sections
were placed in the developer–silver nitrate–ammonium hy-
droxide solution, followed by fixation in 5% sodium thio-
sulphate. A grid count was performed at 40 magnification
to quantify axonal density using the Axioscope microscope
with a micropublisher 5.0 RTV digital CCD camera
(Qimaging) and Image-Pro Plus 6.3 software.
S1P1 immunohistochemical
quantification
Biopsy and autopsy white matter sections were immunos-
tained for S1P1 as described above and in Supplementary
Table 2. Tiled images were taken. Using Fiji just ImageJ
(Schindelin et al., 2012), the white matter tissue surface area
was calculated and the number of positive cells was manual-
ly counted.
Immunofluorescence and confocal
imaging
Immunofluorescent double-labelling was performed to ana-
lyse multiple sclerosis lesions and perivascular T-cell clusters.
Antigen retrieval and incubation with primary antibodies
was performed as described above. Sections were then incu-
bated with secondary antibodies directly labelled with Alexa
fluorophore Cy3 or Cy5. Alternatively, sections are incu-
bated with biotinylated, secondary antibodies, followed by
incubation with streptavidin labelled with Cy3 or Cy5. Anti-
CD44 rabbit polyclonal antibody staining was enhanced by
Tyramide Signal Amplification (PerkinElmer). Finally, all
sections were incubated with Hoechst (33342; Thermo
Fisher Scientific). Confocal imaging was performed using the
Leica microscope TSA SP8 X at 20, 40, and 63 mag-
nification (Leica Microsystems) using Leica Applications
Suite X software (Fransen et al., 2019). For CD8- and
laminin-stained sections, tiled confocal images of tissue sec-
tions were made at 20 magnification (an example is
shown in Supplementary Fig. 2).
Assessment of T cell location
Localization of T cells was assessed in normal-appearing
white matter, active, mixed active/inactive, and inactive
lesions as described above. Using ImageJ, tissue sections
were systematically examined, and the number of parenchy-
mal and perivascular T cells was counted as described in
Smolders et al. (2018). For donor and tissue information,
see Supplementary Table 3.
Isolation of T cells from fresh
autopsy material
White matter from multiple sclerosis and control cases and
macroscopically visible multiple sclerosis lesions were dis-
sected at autopsy and stored at 4C in Hibernate A medium
(Invitrogen). A small tissue sample was snap-frozen in liquid
nitrogen and stored at –80C for immunohistochemistry.
The remaining tissue was mechanically dissociated as previ-
ously described (Smolders et al., 2013, 2018). Mononuclear
cells were separated from the suspension by Percoll (GE
Healthcare) gradient centrifugation, followed by CD11b
magnetic activated cell sorting (Miltenyi Biotech), as previ-
ously described (Smolders et al., 2013, 2018; Mizee et al.,
2017; van der Poel et al., 2019). After CD11b cell sorting,
the flow-through containing T cells was cryopreserved. The
frozen tissue sample was sectioned at 20 mm, immunostained
for HLA and PLP, and lesions were characterized as
described above and in Supplementary Table 2. Donor and
sample characteristics are described in Supplementary
Table 4. None of the multiple sclerosis cases received immu-
nomodulatory therapies in the year before autopsy.
Flow cytometric analysis
Cells were stained with antibodies for surface markers and
LIVE/DEAD fixable red (Life Technologies) for 30 min at
4C. Subsequently, cells were washed, fixated, and permea-
bilized, followed by intracellular staining (Foxp3/
Transcription Factor Staining Buffer Set, Thermo Fisher
Scientific). Washed cells were analysed at an LSRFortessa
cell analyzer (BD Biosciences). FlowJo software (version 10;
Tree Star, Ashland, OR, USA) was used for subsequent data
analysis. The guidelines for the use of flow cytometry and
cell sorting in immunological studies were followed
(Cossarizza et al., 2017). Specifications of the used antibod-
ies are provided in Supplementary Table 5. Gating strategies
are shown in Supplementary Fig. 3A. T-distributed stochas-
tic neighbour embedding (t-SNE) analysis was performed
with Cytosplore+HSNE software (van Unen et al., 2017).
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Cell sorting and quantitative RT-
PCR
Cryopreserved samples were thawed, washed, blocked with
10% normal horse serum, and stained directly with cocktails
of fluorescently-conjugated antibodies described in
Supplementary Table 5. CD20+ B cells, naı¨ve, memory, ef-
fector CD8+ T and natural killer (NK) cells from blood and
CD103– and CD103+CD69+CD8+ TRM cells from brain
were sorted on a BD FACS Aria II cell sorter (BD
Biosciences). Gating strategies are shown in Supplementary
Fig. 3B. Total RNA was isolated with the RNeasyV
R
mini kit
(QIAGEN), and cDNA was synthesized using the
RevertAidTM First Strand cDNA Synthesis Kit (Thermo
Fisher Scientific). Relative gene expression levels were meas-
ured by quantitative reverse transcription-polymerase chain
reaction (RT-PCR) using Fast SYBRV
R
Green Master Mix
(Applied Biosystems) on a StepOnePlusTM system (Applied
Biosystems) with the cycle threshold method. Donor and
sample characteristics are provided in Supplementary Table
6, and primers are described in Supplementary Table 7.
Microarray data analysis
RNA expression levels for CXCR6 and CXCL16 from
laser-dissected tissue from mixed active/inactive and inactive
demyelinated lesions were obtained from a microarray data-
set (Hendrickx et al., 2017). Adjusted P-values are shown in
Fig. 5.
Statistical analysis
All analyses were performed in GraphPad Prism 6 or 7
(GraphPad Software, San Diego, CA, USA). When data
were not normally distributed non-parametric tests, either
Kruskall-Wallis or Mann-Whitney U-tests were performed.
Dunn’s test was used for multiple comparisons. When data
were normally distributed one-way ANOVA test was used
together with Tukey post hoc test.
Data availability
The data that support the findings of this study are available
from the corresponding author, upon reasonable request.
Results
Multiple sclerosis normal-appearing
white matter is enriched for T cells
We first quantified the presence of CD3+ T cells in normal-
appearing white matter of the pyramidal tract at the level of
the medulla oblongata of multiple sclerosis, Alzheimer’s dis-
ease, and non-neurological control brains (Fig. 1A). Donor
and sample characteristics were comparable for all three
groups (Table 1 and Supplementary Table 1). However,
brain weight was significantly lower in the multiple sclerosis
and Alzheimer’s disease cases compared to the non-neuro-
logical controls, indicating brain tissue loss in the diseased
brains (Supplementary Fig. 4). In multiple sclerosis brains,
more T cells were encountered compared to Alzheimer’s dis-
ease and control brains (Fig. 1B). We then assessed the rela-
tionship between the number of T cells and axonal loss in
pyramidal tract normal-appearing white matter. Axon dens-
ity was significantly reduced in the multiple sclerosis cases
compared to the controls, indicating axonal loss in multiple
sclerosis normal-appearing white matter (Fig. 1C). Axon
density did not correlate with the number of T cells in mul-
tiple sclerosis normal-appearing white matter (Fig. 1D).
Inflammatory active white matter
lesions are enriched for CD4 + and
CD8 + T cells
In sections of subcortical white matter of controls,
Alzheimer’s disease cases, and multiple sclerosis cases con-
taining different lesion types, both lesional and perilesional
white matter were delineated, and CD3+ T cells were quan-
tified (Supplementary Fig. 1). T cell counts in pyramidal
tract and subcortical white matter were comparable for non-
neurological controls; however, T cell counts were higher in
(perilesional) subcortical white matter compared to the pyr-
amidal white matter tract in both the multiple sclerosis and
Alzheimer’s disease cases (cf. Fig. 1B and E).
Perilesional white matter and all multiple sclerosis lesion
types contained more T cells compared to control white mat-
ter, but were comparable to neurodegenerative control white
matter. When compared to multiple sclerosis perilesional
white matter, both active and mixed active/inactive lesions
were enriched for CD3+ T cells (Fig. 1E). This enrichment
was observed both for CD4+ and CD8+ T cells (Fig. 1F and
G), without a skewing of the CD8/CD4 ratio between lesion
types (Supplementary Fig. 5A). Interestingly, the number of
CD8+ T cells was reduced in remyelinated areas (shadow
plaques) compared to inflammatory active and mixed active/
inactive lesions (Fig. 1G). Furthermore, the CD8/CD4 ratio
was variable between donors, but consistent between the dif-
ferent regions of individual donors (Supplementary Fig. 5A
and B). Interestingly, multiple sclerosis donors with a low
CD8/CD4 ratio showed a higher percentage of inactive
remyelinated areas in all dissected tissue blocks compared to
donors with a high CD8/CD4 ratio (Supplementary Fig.
5C). Because CD8+ T cells were, next to active lesions, also
more closely associated with mixed active/inactive lesions,
our further analysis focused on CD8+ T cells.
CD8 + T cells are restricted to the
PVS, except in inflammatory active
and mixed active/inactive lesions
We next assessed the localization of CD8+ T cells in mul-
tiple sclerosis normal-appearing white matter, mixed active/
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Figure 1 T cell numbers are increased in multiple sclerosis normal-appearing white matter and further enhanced in inflamma-
tory active and mixed active/inactive lesions. (A) Illustration of experimental set-up. (B) Number of CD3+ cells in the pyramid tract of
non-neurological control (Con) white matter, Alzheimer’s disease neurodegenerative white matter, and multiple sclerosis normal-appearing white
matter at a standardly dissected location at the level of the medulla oblongata (Kruskall–Wallis test P = 0.0002). (C) Axonal density in control
white matter and multiple sclerosis normal-appearing white matter in the pyramid tract. (D) Correlation of axonal density with the number of T
cells in multiple sclerosis normal-appearing white matter in the pyramid tract. (E) Number of CD3+ cells in subcortical white matter lesions
(Kruskall–Wallis test P5 0.0001). (F) Number of CD4+ cells in subcortical white matter lesions in active and mixed active/inactive lesions com-
pared to normal-appearing white matter and remyelinated areas (Kruskall–Wallis test P5 0.0001). (G) Number of CD8 + cells in subcortical
white matter in active and mixed active/inactive lesions compared to normal-appearing white matter (Kruskall–Wallis test P5 0.0001).
(H) Confocal images of CD8 and laminin immunofluorescent staining from control white matter, normal-appearing white matter, active lesion,
mixed active/inactive lesion, and inactive lesion. Scale bars = 50 lm. (I) Percentage of CD8 + cells located in brain parenchyma (Kruskall–Wallis
test P = 0.0042). Note that the quantification of control white matter CD8+ cells in brain parenchyma has been published previously (Smolders
et al., 2018) and is shown here for comparison. Kruskall-Wallis and Dunn’s post hoc test were used and P-values are shown in the plots. ConWM
= control white matter; mA/I = mixed active/inactive; MS = multiple sclerosis; NAWM = normal-appearing white matter; NDWM = neurodege-
nerative white matter.
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inactive lesions, and inactive lesions, by staining the laminin-
gamma subunit in basement membranes. The PVS, the
Virchow–Robin space, is the only compartment in the
human body delineated by two basement membranes, cov-
ered on the luminal side by specialized endothelium and on
the parenchymal side by the glia limitans (Sorokin, 2010).
These basement membranes contain various matrix proteins,
including different laminin chains and collagen type IV (van
Horssen et al., 2005). In multiple sclerosis normal-appearing
white matter, CD8+ T cells were found almost exclusively in
the PVS, comparable to control white matter (Fig. 1H). In
active and mixed active/inactive lesions, an increased propor-
tion of CD8+ T cells infiltrated the brain parenchyma (me-
dian 13.9% and 16.5%, respectively). In inactive lesions, the
percentage of parenchymal CD8+ T cells was comparable to
the multiple sclerosis normal-appearing white matter
(Fig. 1I).
Progressive multiple sclerosis
donors show perivascular cuffing of
T cells
In the multiple sclerosis normal-appearing white matter, we
occasionally observed large clusters of T cells restricted to
the PVS, which were previously characterized as perivascular
cuffs (Revesz, 1994). We systematically scored all medulla
oblongata sections for the presence of perivascular T-cell
cuffing (Fig. 2A). T cell cuffs were only encountered in the
progressive multiple sclerosis donors (Fig. 2B). Interestingly,
donors with perivascular cuffs showed a higher number of
demyelinated lesions in the brainstem and a higher percent-
age of mixed active/inactive lesions (Fig. 2C and D). There
were no significant differences in the percentage of remyeli-
nated active lesions or the number of reactive sites in the
brainstem and the total disease duration or time from first
symptoms until the patient needed a walking aid (data not
shown).
Multiple sclerosis lesion T cells
show a CD8 + TRM cell surface
marker profile
We next analysed rapidly-isolated post-mortem mono-
nuclear cells for the expression of phenotypic markers that
we recently identified on human brain TRM cells by flow
cytometry (Smolders et al., 2018). These included the canon-
ical markers CD69 and CD103 (Szabo et al., 2019), but
also programmed death receptor 1 (PD-1), very late antigen-
1 (VLA-1, CD49a), and the general memory marker CD44
(Kumar et al., 2017). Cells were acquired from fresh mul-
tiple sclerosis tissue blocks containing either mixed active/in-
active (n = 3) or active (n = 5) lesions, multiple sclerosis
normal-appearing white matter (n = 7), and control white
matter tissue (n = 10) (Fig. 3A, donor and sample informa-
tion in Supplementary Table 4).
Virtually all T cells isolated from multiple sclerosis lesions
were CD69+, with both a CD103+ and a CD103– fraction
present (Fig. 3B). There was a lower fraction of
CD69–CD103–CD8+ T cells in multiple sclerosis lesions
compared to control white matter (Fig. 3C).
Figure 2 Clinical and pathological correlates of perivascu-
lar cuffing of CD3 + cells at a standardly dissected location
at the level of the medulla oblongata. (A) CD3+ perivascular
cuff showing more than one ring of CD3+ cells around a blood ves-
sel at the level of the medulla oblongata. Scale bar = 50 lm. (B)
Multiple sclerosis cases with perivascular cuffing more often show a
progressive multiple sclerosis disease course (chi-square test
P = 0.017). (C and D) Multiple sclerosis cases with perivascular cuff-
ing show a higher brainstem demyelinated lesion load (C) and a
higher percentage of mixed active/inactive lesions (D). Mann-
Whitney U-test was used, and P-values are shown in the plots. BRS
= brainstem; mA/I = mixed active/inactive; PP = primary progres-
sive; SP = secondary progressive.
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Figure 3 CD8 + T cells in multiple sclerosis lesions show a TRM cell surface marker profile. (A) An example of PLP and HLA staining
of a multiple sclerosis mixed active/inactive lesion dissected for cell isolation. Scale bar = 1 mm (PLP) and 100 lm (HLA). (B) Flow-cytometric
plots for CD103, CD69, PD-1, and CD49a expression on CD8+ T cells from multiple sclerosis normal-appearing white matter and lesions.
(C) Percentage of single- and double-positive cells for CD69 and CD103 in control white matter, multiple sclerosis normal-appearing white mat-
ter, and multiple sclerosis lesions. (D) Percentage of PD-1 + and CD49a + CD8 + T cells is comparable in control white matter, multiple sclerosis
normal-appearing white matter, and multiple sclerosis lesions. PD-1 and CD49a expression is increased in CD103+ cells. (E) Multiple sclerosis
normal-appearing white matter and multiple sclerosis lesion CD8+ TRM cells are CD44
bright. (F) In the PVS of multiple sclerosis normal-appearing
white matter, CD44 + T cells are located in close contact to the CD44 ligand, laminin. Scale bar = 25 lm. (G) In the inactive centre of mixed ac-
tive/inactive lesions, CD44 + T cells are present in the PVS. The basal lamina in inactive centres appears fibrotic. Scale bar = 25 lm. (H) T cell
clusters in multiple sclerosis perivascular cuffs show high CD44 expression. Scale bar = 10 lm. Con = control; mA/I = mixed active/inactive; MS
= multiple sclerosis; NAWM = normal-appearing white matter; NDWM = neurodegenerative white matter.
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Because the presence of CD103 impacts on the phenotype of
brain TRM cells (Wakim et al., 2012; Smolders et al., 2018), we
stratified further analyses for expression of CD103. Expression
of the TRMmarkers PD-1, CD49a, and CD44 was equally high
on CD8+ T cells from all three categories of tissue subtypes
sampled (Fig. 3B, D and E). Interestingly, CD49a is a receptor
for collagen type IV andCD44 can act as a receptor for laminin,
among others, and both molecules may hereby modulate hom-
ing of brain TRM cells in the PVS (Topham and Reilly, 2018).
CD44+ lymphocytes could also be observed in close contact
with laminin in the PVS with immunohistochemistry in both
normal-appearing white matter and inactive centres of multiple
sclerosis lesions (Fig. 3F and G). Perivascular T cell clusters
showed high expression of CD44 (Fig. 3H).
Circulating T cells are almost
absent in chronic multiple sclerosis
autopsy lesions
Next we compared the presence of S1P1+ circulating T cells
and the CD103+ TRM cell subset in both inflammatory ac-
tive lesions from early multiple sclerosis biopsy cases and
chronic progressive multiple sclerosis autopsy cases. In both
lesion stages, we encountered CD103+ TRM cells in the
brain parenchyma (Fig. 4A). In the early multiple sclerosis
lesion stages, a relatively smaller proportion of CD3+ T cells
was CD103+ compared to the chronic progressive multiple
sclerosis autopsy cases (Fig. 4B), which suggests a smaller
pool of CD103+ TRM cells in early multiple sclerosis lesions.
We stained for the recirculation marker S1P1 and found, in
accordance with earlier studies (Van Doorn et al., 2010;
Brana et al., 2014; Machado-Santos et al., 2018), no stain-
ing of S1P1+ T cells in the parenchyma or PVS of biopsy or
autopsy material. Almost all S1P1+ cells in biopsy samples
were located directly adjacent to the luminal side of the
endothelium (Fig. 4C). However, where few intravascular
S1P1+ T cells were found in inflammatory active lesions
from chronic progressive multiple sclerosis autopsy, they
were present at high number in lesions from early multiple
sclerosis biopsies (Fig. 4C and D). Although a post-mortem
effect cannot be excluded, desensitization of S1P1 is an im-
portant mechanism for effector T cells to migrate from the
circulation into tissues (Arnon et al., 2011). Close contact
with the endothelium suggests that T cells in early multiple
sclerosis biopsies may reflect an expanded local pool of
intravascular effector-type T cells, which may lose S1P1
upon infiltration of the PVS. This interpretation would sup-
port a role for non-TRM cells in early multiple sclerosis,
which was not observed in end-stage multiple sclerosis.
T-SNE analysis identifies exclusively
CD8 + TRM cell clusters in multiple
sclerosis cases
To evaluate the presence of small T cell clusters lacking a
TRM cell phenotype in lesions, which may get lost in
conventional gating strategies, we generated t-SNE plots of
the total CD3+CD8+ T cell fraction. Only in the control
donors, unique clusters of cells displaying a non-TRM cell
phenotype were encountered, characterized by a lack of
CD69 expression (Fig. 5A, clusters 1 and 2). These cells
showed low expression of TRM cell surface markers and, in
cluster 2, high expression of molecules related to cytotoxicity
(granzyme B and GPR56). In multiple sclerosis normal-
appearing white matter and lesions, dominant T-cell clusters
showed a TRM cell phenotypic profile with clusters 5 and 9
being characterized by high expression of CD103.
CD8 + TRM cells in multiple sclerosis
lesions upregulate the tissue
homing receptor CXCR6
CXCR6 is a core TRM cell marker and a chemokine receptor
mediating tissue infiltration of CD8+ T cells (Kumar et al.,
2017). The percentage of CXCR6+ CD8+ T cells was
increased in multiple sclerosis lesions compared to control
white matter in both the CD103+ and CD103– CD8+ T-cell
population (Fig. 5B and C). In addition, whole tissue gene
expression microarray analysis of laser-dissected control
white matter as well as mixed active/inactive and inactive
multiple sclerosis lesions (Hendrickx et al., 2017) revealed
increased expression of CXCR6 in the rim of mixed active/
inactive lesions (Fig. 5D). The ligand of CXCR6, CXCL16,
is also upregulated in the rim of mixed active/inactive
lesions, indicated by quantitative RT-PCR (Hendrickx et al.,
2013) and by microarray analysis (Fig. 5D). CXCR6–
CXCL16 interaction may mediate homing of CD8+ T cells
in the inflamed parenchyma because these are found in the
inflammatory active rim of mixed active/inactive lesions in
close contact to CXCL16+ cells [median (interquartile range,
IQR) 42.8% (34.9–43.9%) of parenchymal T cells; n = 3]
(Fig. 5E and F).
Lesional CD8 + TRM cells show signs
of reactivation without notable
cytotoxicity
To assess the activation status of brain TRM cells, we
stained for Ki-67. Ki-67 is a marker for T cells undergoing
antigen-specific proliferation in vitro (Soares et al., 2010).
In cells isolated from lesions, higher expression of Ki-67,
as measured by the geometric mean fluorescence intensity
(GMFI), was observed when compared to control white
matter with flow cytometry (Fig. 6A and B), which can in-
dicate an increased rate of recent reactivation. The T-cell
clusters in the PVS contained CD3+ T cells positive for
Ki-67 with immunohistochemistry (Fig. 6C and D).
Next, we analysed expression of the cytotoxic enzyme
granzyme B, which was earlier observed with immunohisto-
chemistry in CD8+ T cells in active lesions (van Nierop
et al., 2017; Machado-Santos et al., 2018). Using immuno-
histochemical staining, we encountered low numbers of
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Figure 4 CD103 + T cells infiltrate the brain parenchyma in early biopsy and chronic autopsy multiple sclerosis lesions, while
circulating S1P1 + T cells are almost absent in chronic autopsy cases. (A) Confocal images of CD3 and CD103 immunofluorescent
staining showing CD103 + T cells in both the PVS and the brain parenchyma in both early and chronic multiple sclerosis lesions. The bright green
signal inside the blood vessel lumen is autofluorescence from erythrocytes. Scale bars = 50 lm. (B) The percentage of CD103 + T cells was
increased in chronic multiple sclerosis lesions (Mann-Whitney U-test P = 0.0023) (C) S1P1 + are present mostly in early multiple sclerosis lesions
and located within the blood vessel lumen, confirming these are circulating T cells. Scale bars = 50 lm. (D) The absolute number of S1P1 + cells
in blood vessels is decreased in chronic multiple sclerosis autopsy lesions compared to early multiple sclerosis biopsy lesions that are both inflam-
matory active (Kruskall–Wallis test P = 0.0017). The total number of T cells was decreased in chronic multiple sclerosis lesions compared to
early multiple sclerosis lesions (Kruskall-Wallis test P = 0.0001). The relative number of S1P1+ T cells was lower in chronic multiple sclerosis
lesions compared to early multiple sclerosis lesions (Kruskall-Wallis test P = 0.049). Dunn’s post hoc test was used and P-values are shown in the
plots. Con WM = control white matter; MS = multiple sclerosis.
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granzyme B+ cells in inflammatory active multiple sclerosis
lesions [median (IQR) = 0.017 (0.012–0.026) per mm2 in
12 tissue sections containing inflammatory active multiple
sclerosis lesions; Fig. 6E], while these tissue sections con-
tained high numbers of CD3+ cells [median (IQR) = 36.9
(11.1–39.6) per mm2]. We observed with flow cytometry
equally low numbers of granzyme B+ CD8+ T cells in
fractions from control white matter and multiple sclerosis
normal-appearing white matter and lesions (Fig. 6F). In ac-
cordance with earlier data, lowest granzyme B expression
was observed in the CD103+ TRM cell subset (Smolders
et al., 2018). Therefore, our data do not support an upregu-
lation of granzyme B as cytotoxic effector molecule by
lesional TRM cells.
Figure 5 Multiple sclerosis normal-appearing white matter and multiple sclerosis lesions show a distinct TRM cell surface
marker profile with a higher percentage of CXCR6 + CD8 + T cells in multiple sclerosis lesions. (A) T-SNE analysis of all
CD3 + CD8 + T cells reveals distinct cell clusters in control white matter, multiple sclerosis normal-appearing white matter, and multiple sclerosis
lesions. The heat map shows the expression pattern in the indicated Tcell clusters. (B) Flow cytometric plots for CXCR6 and CD69 expression
on CD8 + TRM cells in control white matter, normal-appearing white matter, and multiple sclerosis lesion samples. (C) CXCR6 is upregulated in
multiple sclerosis lesions in both CD103– and CD103 + cells (Kruskall-Wallis test P = 0.0357). (D) Tissue mRNA gene expression levels from
mixed active/inactive lesions shows upregulation of CXCR6 and its ligand, CXCL16. (E) CD8 + T cells are found in brain parenchyma in the mixed
active/inactive lesion rim. Scale bar = 50 lm. (F) CD3 + T cells in close contact to a CXCL16 + cell in an inflammatory active multiple sclerosis
lesions. Scale bar = 5 lm. Mann-Whitney U- and Kruskall-Wallis tests were used, and (adjusted) P-values are shown in the plots. Con WM =
cnotrol white matter; mA/I = mixed active/inactive; MS = multiple sclerosis; NAWM = normal-appearing white matter.
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Figure 6 CD8 + TRM cells in multiple sclerosis lesions are reactivated and show increased expression of GPR56 without upregu-
lation of granzyme B. (A) Ki-67 signal in CD8+ TRM cells from multiple sclerosis normal-appearing white matter and multiple sclerosis lesions.
(B) In multiple sclerosis lesion CD8+ TRM cells upregulate Ki-67 expression compared to controls, both in CD103
+ and CD103– TRM cells
(Kruskall-Wallis test P = 0.0081). (C) T cells within perivascular cuffs are Ki-67 + . Scale bar = 25 lm. (D) Expression of nuclear Ki-67 in CD3+ T
cells. Scale bar = 5 lm. (E) Immunohistochemistry of a granzyme B + cell in a subcortical white matter multiple sclerosis lesion. Scale bar = 25
lm. (F) There is no difference in the percentage of granzyme B + cells derived from multiple sclerosis lesions compared to control white matter.
(G) Brain TRM cells show GPR56
dim expression, with a higher percentage of positive cells in CD103 + compared to CD103– TRM populations.
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The adhesion G protein-coupled receptor GPR56 is
expressed at high levels on circulating cytotoxic lympho-
cytes, where it inhibits immediate effector functions (Chang
et al., 2016). Previously, we found almost no GPR56high ex-
pression on CD8+ brain TRM cells (Smolders et al., 2018).
In multiple sclerosis lesions, we saw an expansion of a
GPR56dim subset in the CD8+CD69+CD103+ TRM cell
fraction (Fig. 6G–I). This CD103+ cell-restricted expansion
was confirmed by quantitative RT-PCR (Fig. 6J). Expression
of GPR56 may reflect cytotoxic capacity of multiple sclerosis
lesion brain TRM cells but may also restrict granzyme B
expression.
Perivascular cuffs show signs of TRM
cell reactivation
In search for the site of TRM cell reactivation, we stained the
perivascular cuffs for antigen presentation and reactivation
markers. As shown above, Ki-67+ CD3+ T cells were
observed in these clusters (Fig. 6C and D), suggesting that
reactivation could occur in these perivascular cuffs. Within
the perivascular T cell cuffs, large populations of
CD3+CD103+ TRM cells were observed (Fig. 7A). A median
proportion of 73.1% (IQR 64.7–84.6%) of these TRM cells
showed expression of E-cadherin, the ligand for CD103,
which may be involved in clustering of these cells (Topham
and Reilly, 2018) (Fig. 7B; n = 3). In the perivascular cuffs,
we found CD103+ TRM cells in close proximity to HLA
+
(Fig. 7C and D) and CD163+ (Fig. 7E) perivascular macro-
phages and CD20+ B cells (Fig. 7F), which could both be
involved in antigen presentation and reactivation of TRM
cells within the PVS in chronic multiple sclerosis cases and
accumulating in mixed active/inactive lesions.
Discussion
Here we provide an extensive analysis of the phenotypic
profile and spatial localization of human brain T cells in re-
lation to the post-mortem pathology of advanced multiple
sclerosis. We show that the number of T cells is increased in
multiple sclerosis normal-appearing white matter and is
enhanced further in inflammatory active multiple sclerosis
white matter lesions. In line with previous reports (Smolders
et al., 2013, 2018; van Nierop et al., 2017; Machado-Santos
et al., 2018), we show that these are mostly CD8+ TRM
cells, which lack characteristics of circulating lymphocytes.
We expand previous work by elaborating on the phenotypic
and functional profile of these cells and associating their
characteristics with the localization in the PVS. In multiple
sclerosis normal-appearing white matter, CD8+ TRM cells
were retained in the PVS, likely mediated by high expression
of CD44 and CD49a. We found that clustering of CD8+
TRM cells in perivascular cuffs is only observed in donors
with progressive multiple sclerosis. In mixed active/inactive
lesions, CD8+ TRM cells also localized in the brain paren-
chyma. This is possibly mediated by high expression of the
tissue homing receptor CXCR6 by lesional CD8+ TRM cells,
since its ligand CXCL16 also shows increased expression in
the mixed active/inactive lesion rim. CD8+ TRM cells in mul-
tiple sclerosis lesions showed a higher expression of Ki-67,
presumably reflecting recent reactivation. We observed anti-
gen-presenting cells in conjunction with Ki-67+ TRM cells in
the perivascular cuffs, suggesting that these are potential hot-
spots of this reactivation. We further observed a low expres-
sion of granzyme B, which could be due to the high
expression of inhibitory GPR56. The quantities, localization,
and activation state of these cells, together with the associ-
ation of perivascular T cell clusters with lesion load, mixed
active/inactive lesions, and progressive disease, suggest that
reactivation of CD8+ TRM cells in the PVS is a key mechan-
ism in the maintenance of white matter lesion activity in
advanced progressive multiple sclerosis.
Only in demyelinated white matter lesions did we observe
substantial numbers of CD8+ TRM cells outside the PVS.
Generating cytotoxic mediators, such as granzyme B, is an
effector mechanism of reactivated TRM cells (Mueller and
Mackay, 2016). Surprisingly, we did not find an enrichment
of granzyme B+ cells in the cell fraction isolated from
lesions. This finding contrasts with an enrichment for gran-
zyme B+ T cells in multiple sclerosis lesions reported by Van
Nierop et al. (2017). A sampling error is unlikely as only
few granzyme B+ cells were stained with immunohistochem-
istry in lesions as well. This does not suggest an upregulation
of the granzyme B–perforin axis in chronic multiple sclerosis
lesions as was observed in early multiple sclerosis diagnostic
biopsy samples (Konjevic Sabolek et al., 2019). In general,
brain CD103+ TRM cells show low expression of granzyme
B and are almost devoid of perforin (Smolders et al., 2013,
2018). One of the reasons for this lack of cytotoxicity could
be the expression of intermediate levels of GPR56 by mul-
tiple sclerosis lesional CD103+ TRM cells. GPR56 is
Figure 6 Continued
(H) Some multiple sclerosis normal-appearing white matter and multiple sclerosis lesion TRM cells show GPR56
dim expression. (I) The percent-
age of GPR56dim cells is increased in CD69 + CD103 + CD8 + TRM cells derived from multiple sclerosis lesions compared to control white matter.
(J) Relative gene expression for ADGRG1 (GPR56) in FACS-sorted CD20+ B cells, naı¨ve, memory, effector CD8+ T cells, and NK cells from per-
ipheral blood and CD103– and CD103 + CD69 + CD8 + TRM cells from brain samples showing increased ADGRG1 expression in CD103
+ cells.
Sample 1 (blue circles) and sample 2 (red circles) were pooled cells from derived from five and three donors, respectively. Mann-Whitney U-test
was used, and P-values are shown in the plots. Con = control; GMFI = geometric mean fluorescence intensity; MS = multiple sclerosis; NAWM
= normal-appearing white matter.
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expressed at high levels on circulating lymphocytes with
cytotoxic capacities, where it inhibits effector functions
(Chang et al., 2016). In normal white matter, human post-
mortem CD8+ TRM cells produce more granzyme K than
granzyme B (Smolders et al., 2013, 2018), which could also
serve as an effector molecule in multiple sclerosis lesions.
Furthermore, CD8+ TRM cells express high levels of the in-
hibitory receptor PD-1. Previously, we observed expression
of its ligand, programmed death-ligand 1 (PD-L1), in mul-
tiple sclerosis lesions but not in control white matter
Figure 7 Perivascular cuffs consist of CD103 + TRM cells in close contact with perivascular macrophages and B cells suggesting
antigen presentation and reactivation of TRM cells in the perivascular space. (A) CD3
+ T cells in perivascular clusters express
CD103. (B) CD3 + T cells in perivascular clusters express the ligand for CD103, E-cadherin. (C) HLA + perivascular macrophages are present in
perivascular cuffs. (D–F) In perivascular cuffs, CD103 + TRM cells are found in close proximity to HLA
+ and CD163 + perivascular macrophages
(D and E) and to CD20 + B cells (F). Scale bars = 10 lm in A–C and 5 lm in D–F.
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(Smolders et al., 2018). In polyomavirus-infected mice, ex-
pression of PD-L1 was observed on myeloid cells, microglia,
and astrocytes (Shwetank et al., 2019). Conversely, blockade
of the PD-1 system in treatment of human melanoma
patients with immune checkpoint inhibitors has been associ-
ated with the occurrence of multiple sclerosis-like demyeli-
nating lesions (Maurice et al., 2015; Dur~aes et al., 2018).
Cytokine production by activated CD8+ TRM cells could
contribute to the maintenance of mixed active/inactive
lesions. Human white matter CD8+ TRM cells are potent
producers of IFNc, granulocyte-macrophage colony-stimu-
lating factor, and tumour necrosis factor upon activation
(Smolders et al., 2018). Also, Fas ligand-mediated killing of
Fas-expressing oligodendrocytes around multiple sclerosis
lesions could be a potential mechanism by which CD8+ T
cells contribute to demyelination in chronic multiple sclerosis
lesions (D’Souza et al., 1996; van Nierop et al., 2017;
Fransen et al., 2019; Wagner et al., 2020).
In multiple sclerosis normal-appearing white matter,
CD8+ TRM cells were observed in their normal compart-
ment, the PVS. Within this compartment, accumulation of
inflammatory cells in perivascular cuffs has since long been
recognized as an important pathological feature of multiple
sclerosis (Prineas and Wright, 1978). In our dataset, perivas-
cular cuffing at the medulla oblongata was only observed in
progressive multiple sclerosis. Earlier studies found perivas-
cular cuffing to be more prevalent in brain donors with sec-
ondary progressive multiple sclerosis compared to primary
progressive multiple sclerosis (Revesz et al., 1994). We now
show these cuffs to contain T cells expressing the TRM cell
marker CD103. Gray et al. earlier argued that TRM cell clus-
tering with antigen-presenting cells, CD163+ perivascular
macrophages and B cells, could be the first step of ectopic
lymphoid structure formation found in several inflammatory
diseases (Gray et al., 2018). In post-mortem multiple scler-
osis studies, ectopic lymphoid structures are prevalent in the
meninges of progressive donors (Serafini et al., 2004; Haider
et al., 2016; Machado-Santos et al., 2018) and may reflect
mechanisms similarly to the role of perivascular cuffing.
This idea is further supported by studies that show that the
PVS and the meningeal compartment are connected
(Dendrou et al., 2015; Louveau et al., 2015, 2016).
There are some limitations to our work. First, cells were
isolated from tissue blocks containing both multiple sclerosis
normal-appearing white matter and multiple sclerosis
lesions, which may dilute differences in T cell phenotypes be-
tween both locations. As we did not use enzymes during the
isolation procedure, we likely isolated only a proportion of
cells from the brain tissue but on the other hand did not
skew phenotypes by enzymatic digestion. Earlier studies
showed that isolation procedures target subsets of tissue-resi-
dent cells and create skewing in phenotypes found (Steinert
et al., 2015). These aspects are covered by the combination
with immunohistochemistry to validate our findings. Last,
the overall numbers of cells sampled from tissue blocks are
quite low, when compared to flow cytometric studies on per-
ipheral blood mononuclear cells. This did not allow
sequencing of the brain TRM cell transcriptome. In particu-
lar, the number of CD4+ T cells we isolated for flow cytom-
etry studies was relatively low for reliable assessment.
Strengths of our work are the well-characterized donor co-
hort and lesions, the combination of flow cytometry and
immunohistochemistry, and the sample size.
Interestingly, in subcortical white matter from neurodege-
nerative controls we observed a comparable number of T
cells compared to multiple sclerosis cases. This finding may
relate to the lower weight of the Alzheimer’s disease brains
and/or the neurodegenerative process and is in line with two
earlier reports on T cell numbers in relation to Alzheimer’s
disease pathology (Zotova et al., 2013; Merlini et al., 2018).
It would be interesting to study differences in effector func-
tions in Alzheimer’s disease-associated TRM cells potentially
involved in a neuroinflammatory response in neurodegenera-
tive diseases. However, our data suggest that in advanced
multiple sclerosis cases, the TRM cell response in normal-
appearing white matter is not solely part of a neuroinflam-
matory response to the axonal damage, since we did not
find a correlation with axonal density.
Furthermore, genetic risk factors for multiple sclerosis in
immune-related genes (Attfield et al., 2012; Dendrou et al.,
2015), effectiveness of therapies directed at circulating lym-
phocytes in the earlier stage of the disease (Wingerchuk and
Weinshenker, 2016), and pathological features of chronic
multiple sclerosis, like the lymphocytic infiltrates found in
both PVS and meninges that mimic other immune-mediated
diseases (Corsiero et al., 2016), all lead us to think of mul-
tiple sclerosis as a primary immune-mediated disease.
Therefore, a main open question is which antigen is pre-
sented to the CD8+ TRM cells in the PVS of these chronic
progressive multiple sclerosis brain donors. In other human
and animal tissues investigated, TRM cell populations appear
to control local viral infections (Szabo et al., 2019). In mod-
els of CNS neurotropic virus infection, local brain CD8+
TRM cell populations are generated against vesicular stoma-
titis virus (Wakim et al., 2010), mouse polyomavirus
(Shwetank et al., 2019), West Nile virus (Aguilar-Valenzuela
et al., 2018), and non-replicating adenoviruses (Schøller
et al., 2019). This supports an antiviral response as a poten-
tial driver of CD8+ TRM cell recruitment in the CNS, which
may also be applicable to multiple sclerosis lesions. In a
mouse model for multiple sclerosis, it was recently shown
that viral infections during early life precipitate brain auto-
immune disease by an increased recruitment of TRM cells
into the brain (Steinbach et al., 2019). In accordance, elec-
tron microscopy studies showed paramyxovirus-like fuzzy
filament in nuclei of lymphocytes and macrophages in mul-
tiple sclerosis perivascular cuffs (Tanaka et al., 1975), which
could reflect the initiation of an antiviral T-cell response
(Prineas, 1972). Identification of the exact cells expressing
viral antigens and provoking subsequent CD8+ TRM cell ex-
pansion could provide a critical avenue towards understand-
ing the cause of multiple sclerosis. However, as low numbers
of perivascular CD8+ TRM cells are also observed in donors
without multiple sclerosis (Smolders et al., 2018), the
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antigen presented to TRM cells in multiple sclerosis could be
present both in donors with and without multiple sclerosis.
Differences in genetic and environmental background
could—in this scenario—accumulate in the destructive im-
mune response seen in multiple sclerosis.
Altogether, our findings point to the PVS as a new frontier
for progressive multiple sclerosis treatment development.
Understanding the mechanisms that are involved in CD8+
TRM cells expanding in the PVS, entering mixed active/in-
active lesions, and driving ongoing inflammatory lesion ac-
tivity could provide targets for new disease-modifying
therapies with efficacy in progressive multiple sclerosis.
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